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HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are
Associated With Inflammation Level, Disease Activity, and the
Health Assessment Questionnaire Score in Patients With
Inflammatory Polyarthritis
Stephanie F. Ling,1 Sebastien Viatte,1 Mark Lunt,1 Alper M. Van Sijl,2 Lucia Silva-Fernandez,3
Deborah P. M. Symmons,4 Adam Young,5 Alexander J. Macgregor,6 and Anne Barton4
Objective. Rheumatoid arthritis (RA) susceptibility
HLA–DRB1 haplotypes based on amino acid positions 11/
13, 71, and 74 predict radiographic damage. Themechanism
of action is unknown, but it may be mediated by inflamma-
tion. We undertook this study to systematically investigate
the effect of these amino acids on nonradiographicmeasures
of disease activity/outcomes.
Methods. We tested the association of RA suscepti-
bility HLA–DRB1 amino acids with the C-reactive protein
(CRP) level, the tender joint count (TJC), the swollen joint
count (SJC), theDisease Activity Score in 28 joints (DAS28),
and the Health Assessment Questionnaire (HAQ) score
in the Norfolk Arthritis Register (NOAR) and Early Rheu-
matoid Arthritis Study (ERAS) cohorts. Longitudinal
modeling of disease activity/outcomes was performed using
generalized linear latent and mixed models. Mediation ana-
lysis was performed using directed acyclic graphs to investi-
gate the paths from genetic factors to outcome.
Results. A total of 2,158 patients were available for
analysis in the NOAR cohort. Valine at position 11 showed
the strongest association with the CRP level (P5 2.21 3
1026), the SJC (P5 7.51 3 1026), and the DAS28
(P5 0.002); it was marginally associated with the HAQ
score (P5 0.044) but not with the TJC. The same amino
acid and haplotype risk hierarchy observed for susceptibility
and radiographic severity was observed for the CRP level
and nonradiographic measures of disease activity/outcome,
apart from the TJC. The results were replicated in the ERAS
cohort. The effect of valine at position 11 on the SJC was
mainly mediated by anti–citrullinated protein antibody sta-
tus, the effect of which was mainly mediated by inflamma-
tion; however, the effect of valine at position 11 was also
independent of theCRP level (P5 1.63 1024).
Conclusion. Genetic markers of RA susceptibility
located within HLA–DRB1 determine the levels of clinical
and systemic inflammation independently, and also deter-
mine all objectivemeasures of disease activity and outcome.
The shared epitope (SE) hypothesis postulates that
HLA–DRB1 alleles sharing a similar amino acid motif
at positions 70–74 confer susceptibility to rheumatoid
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arthritis (RA) (1). However, it has recently been demon-
strated that a model including amino acids at positions 11
or 13 (both are in tight linkage disequilibrium [LD]), 71,
and 74 better explains the association of HLA–DRB1 with
RA susceptibility (2).
Amino acid combinations from these 3 positions
(which are in partial LD with one another) form 16 hap-
lotypes hierarchically classified with regard to their effect on
RA susceptibility (from conferring risk to conferring protec-
tion) (2). They are independently associated with radio-
graphic damage and mortality, with an identical risk
hierarchy between susceptibility and radiographic severity,
demonstrating that position 11/13 (outside the SE) also con-
tributes to progression and outcome (3). Valine at position
11 has been reported to influence radiographic progression
in RA patients in 2 further independent cohorts (4,5).
However, it is unclear by what mechanism the 16-
haplotype model results in radiographic damage. Previous
work has suggested that high levels of C-reactive protein
(CRP) correlate with radiographic outcomes (6); however, it
has also been shown that RA can progress in the absence
of detectable systemic inflammation (7,8). Acute-phase
markers are imperfectly correlated with objective evi-
dence of synovitis, and therefore, the Disease Activity
Score in 28 joints (DAS28) (9), swollen joint count (SJC),
or tender joint count (TJC) may be better markers of
chronic inflammation. It has been shown that clinical (e.g.,
the SJC) rather than laboratory (or systemic) (i.e., the
CRP level or erythrocyte sedimentation rate [ESR]) mea-
sures of inflammation are associated with radiographic
progression and mortality (8), but the correlation of
HLA–DRB1 markers with any measures of inflammation
(clinical or laboratory) has not been studied yet. We
hypothesize that the effect of HLA–DRB1 haplotypes on
outcome is mediated via inflammation.
Therefore, we aimed to first examine underlying
pathways driving radiographic damage by testing genetic
associations of the 16-haplotype model with the CRP
level. Second, we examined genetic associations with other
nonradiographic measures of disease outcome and activity
(including the DAS28 and its subcomponents [TJC, SJC,
and CRP level]) and with disability using the Health
Assessment Questionnaire (HAQ) (10). Third, we per-
formed mediation analysis using directed acyclic graphs to
investigate the relative contribution of different path vari-
ables in the disease process (CRP level, anti–citrullinated
protein antibody [ACPA] status, and the like).
PATIENTS AND METHODS
Patients and cohorts. Two prospective cohorts of patients
with longitudinal outcome data were studied. These were the
Norfolk Arthritis Register (NOAR) (11) and the Early Rheumatoid
Arthritis Study (ERAS) (12) cohorts. NOAR is a primary care–
based inception cohort of 2,158 patients recruited since 1989
(recruitment is still ongoing) presenting with recent-onset inflamma-
tory polyarthritis, defined as having$2 swollen joints for.4 weeks.
Patients recruited between 1989 and 1994 remained under long-
term follow-up (up to 20 years’ duration), with the exception of 1)
patients who did not satisfy the American College of Rheumatology
(ACR) 1987 revised criteria for RA (13) at 5 years of follow-up and
who were diagnosed by a consultant as having disease other than
RA, undifferentiated inflammatory polyarthritis, psoriatic arthritis,
or postviral arthritis to explain their symptoms and 2) patients with
spontaneous long-term remission of their disease, defined as having
no inflamed joints at the third or fifth annual follow-up visits and not
taking disease-modifying antirheumatic drugs (DMARDs)/steroids.
Consequently, patients recruited between 1989 and 1994
were more likely to be followed up after year 5 if they had high dis-
ease severity. This can reduce study power compared to a study
design without these exclusion criteria, but it will not affect the
effect size of genetic markers tested in the present study, as the rel-
ative change in disease activity/severity measures between carriers
and noncarriers of specific genetic markers will be unaffected.
Censoring the study at year 5 or excluding all patients recruited
between 1989 and 1994 would have a much more drastic impact
on power, so the inclusion of such patients is appropriate.
All patients, including RA patients, were called inflamma-
tory polyarthritis patients. Most inflammatory polyarthritis patients
will satisfy the ACR 1987 revised criteria for RA during follow-up.
CRP level was measured at 0, 5, 10, and 15 years; consequently, the
DAS28 using the CRP level was only calculated at these time points
as well. The TJC and SJC were done at 0–3, 5, 10, 15, and 20 years.
HAQ scores were obtained at 0–5, 7–8, 10, 12, 15, 18, and 20 years.
ERAS is a tertiary care–based cohort of 329 adults clini-
cally diagnosed as having RA who were recruited consecutively
from rheumatology outpatient clinics, had a symptom duration of
,2 years, and had no use of second-line medication. Patients who
did not fulfill the ACR 1987 revised criteria for RA (13) continued
to be followed up and were included for analysis. Patients were
excluded if the diagnosis changed from RA (e.g., early RA evolving
to classical systemic lupus erythematosus). The TJC, SJC, ESR,
DAS28 using the ESR, and HAQ score were recorded every year,
with a maximum follow-up of 15 years. The NOAR and ERAS
patients in the present study are the same as those studied in our
previous work (3).
Genotyping. Genotyping was carried out as previously
described (3,14). Sixteen possible haplotypes exist, based on the
combinations of amino acids at HLA–DRB1 positions 11, 71, and
74 (2) (Table 1). Only results from haplotypes with a frequency of
.5% are reported in NOAR, and only results from haplotypes
with a frequency of.10% are reported in ERAS, although analysis
was carried out on all 16 possible haplotypes in both univariate
and multivariate models. A more stringent frequency cutoff was
required in ERAS due to the smaller sample size.
Statistical analysis. Statistical modeling. Since disease
outcome is variable over time and both NOAR and ERAS are
prospective cohorts of patients with multiple records over time
(data available for up to 20 years in NOAR and for up to 15 years
in ERAS), we performed a longitudinal modeling of disease
activity/outcome. The DAS28, TJC, SJC, CRP level/ESR, and
HAQ score were modeled using Stata software version 13.1
(StataCorp) as longitudinal continuous non-normally distributed
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outcome variables using a generalized linear latent and mixed
model (GLLAMM) (15) with discrete random effects and a varying
number of latent classes, depending on the distribution of each vari-
able. An additive model of association was created for all analyses
by creating a numerical variable (0, 1, or 2) for the number of alleles
carried by each patient. An allele is defined either as a specific
amino acid at a specific position or as a haplotype. A haplotype is
defined as a combination of amino acids coded by DNA positions
inherited independently of one another. The statistical effects are
reported for one copy of every allele.
Covariates. When performing longitudinal modeling of
disease outcome, disease duration and patient age are known
factors associated with disease outcome in RA (16,17). We there-
fore adjusted every model for the effect of age at symptom onset
and duration of symptoms at each time point. Orthogonal
polynomials of these variables were added to the model in order to
take the nonlinear relationship between these covariates and disease
outcome into consideration; orthogonal polynomials were used due
to strong correlation between the terms of regular polynomials. The
statistics Akaike’s information criterion and Bayesian information
criterion were used to determine model parameters (e.g., the power
of polynomials) prior to analysis to ensure best model fit. When
subanalysis was carried out to adjust for treatment, we incorporated
a time-dependent categorical treatment variable (presence or
absence of treatment with a DMARD at every time point studied).
The inclusion of further covariates (e.g., ACPA status) is explained
below in the section on mediation analysis.
Data censoring. All time points with available data on
the following variables studied in NOAR were included: TJC,
SJC, and CRP level. Data were censored at 15 years for the
DAS28 and at 5 years for the HAQ score. Data censoring was
carried out because previous work by our group has shown that
radiographic damage at different time points is strongly corre-
lated, but the variance in damage peaks during initial follow-up
and decreases from there onward (17). Consequently, longitudi-
nal modeling must be censored at a time point that depends on
the outcome being studied. A sensitivity analysis was performed
to determine the above censoring cutoffs.
Effect sizes. The effect size of a GLLAMM for the
DAS28, TJC, SJC, and HAQ score is a b coefficient, representing
the change in the dependent variable for every additional copy of
the amino acid or haplotype tested, expressed in the same units.
CRP level and ESR required log transformation for analysis due
to their distributions, so results are reported as percentage change
in CRP level/ESR, following exponentiation of the b coefficient.
Effect sizes are reported per copy of every allele, compared to a
reference group. Effect sizes would be larger if expressed for
homozygote carriers and if the reference group would be a pro-
tective genotype. As an example, the average difference in the
DAS28 between a VKA homozygote carrier (higher risk haplo-
type) (Table 1) and an SEA homozygote carrier (lower risk or
protective haplotype) (Table 1) is calculated as follows: bVKA
homozygote5 2bVKA – 2bSEA, wherebSEA is less than zero.
Multiple testing. The associations of individual amino
acids, positions, and haplotypes with all outcome variables were
systematically tested in univariate and multivariate analyses. Cor-
rection for multiple testing in univariate analyses was carried out
using the Benjamini-Hochberg false discovery rate method.
Tests of correlation. Tests of correlation between mea-
sures of radiographic damage (assessed by the Larsen score
[18]) and nonradiographic measures of disease outcome/activity
(the SJC, TJC, DAS28, and HAQ score) were performed with
Spearman’s rho (non-normally distributed variables). Correla-
tion between effect sizes of regression analyses (genetic markers
of RA susceptibility versus nonradiographic measures of disease
outcome) was assessed with linear regression (Figure 1).
Mediation analysis. Mediation analysis was performed
to evaluate the extent to which genetic effects on disease out-
come could be explained by their effects on intermediate param-
eters (ACPA status, CRP level). ACPA status (seropositive/
seronegative) was determined with the second-generation CCP2
assay and therefore corresponds to anti–cyclic citrullinated pep-
tide antibody status. First, we drew directed acyclic graphs repre-
senting our working hypothesis (Figure 2). Second, a GLLAMM
was used to fit models that could be considered causal (i.e., all
paths from predictors to outcome consisted only of forward
arrows) as described above (orthogonal polynomials of age and
disease duration as covariates), either with a unique predictor
variable (univariate) or several predictor variables (multivariate),
to determine their relative roles (independent effects or not).
Table 1. Derivations of the 16-haplotype classification, from amino acids at positions 11, 71, and 74
Position 11 Position 71 Position 74
Haplotype
name
Classical
HLA–DRB1 alleles
Valine Lysine Alanine VKA* *04:01
Valine Arginine Alanine VRA* *04:08, *04:05, *04:04, *10:01
Leucine Arginine Alanine LRA* *01:02, *01:01
Proline Arginine Alanine PRA *16:01
Valine Arginine Glutamic acid VRE *04:03, *04:07
Aspartic acid Arginine Glutamic acid DRE *09:01
Valine Glutamic acid Alanine VEA *04:02
Serine Lysine Alanine SKA *13:03
Proline Alanine Alanine PAA* *15:01, *15:02
Glycine Arginine Glycine GRQ* *07:01
Serine Arginine Alanine SRA* *11:01, *11:04, *12:01
Serine Arginine Glutamic acid SRE *14:01
Leucine Glutamic acid Alanine LEA *01:03
Serine Arginine Leucine SRL *08:01, *08:04
Serine Lysine Arginine SKR* *03:01
Serine Glutamic acid Alanine SEA* *11:02, *11:03, *13:01, *13:02
* High-frequency haplotype ($5% study population frequency). The classification system is derived
from Raychaudhuri et al (2).
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The b coefficients along with their 95% confidence intervals
(95% CIs) and P values were used to assess the significance and
importance of each predictor variable and pathway (arrows in
the acyclic graphs).
RESULTS
A total of 2,158 inflammatory polyarthritis patients
for whom we had data on genotype and the variables of
interest were included from the NOAR cohort, and 329
RA patients were included from the ERAS cohort. Demo-
graphic and clinical characteristics of the patients are listed
in Table 2. Of the patients studied in the NOAR cohort,
77% satisfied the ACR 1987 revised criteria for RA (13),
compared with 96% of patients in the ERAS cohort. There
was an important difference in the proportion of ACPA-
positive patients between the NOAR (33%) and ERAS
(90%) cohorts; this was mainly because NOAR is a primary
care inception cohort recruiting all patients with inflamma-
tory polyarthritis within a defined geographic area (19,20),
including those with very low disease severity. As a tertiary
care cohort, ERAS preferentially recruits patients with
higher disease severity; the DAS28, CRP level, and HAQ
score were higher in the ERAS cohort than in the NOAR
cohort (Table 2).
Figure 1. Correlation between genetic markers of susceptibility to rheumatoid arthritis (RA) and nonradiographic measures of outcome. The y-
axes show the effect sizes of HLA–DRB1 haplotypes for their association with nonradiographic measures of RA outcome as determined in this
study (change in C-reactive protein [CRP] level in A; change in swollen joint count [SJC] in B). The x-axes show the effect sizes of the same hap-
lotypes for their association with RA susceptibility (natural logarithm of odds ratios as reported in ref. 3). Linear regression was applied to test
for an association between these effect sizes. Three-letter haplotype names are based on combinations of amino acids at HLA–DRB1 positions
11, 71, and 74. 95% CI5 95% confidence interval.
Figure 2. Directed acyclic graphs and results from the mediation analysis. A, Hypothetical pathways that lead genetic factors encoding, for
example, valine at position 11 of HLA–DRB1, to modulate disease activity/outcome (in this case, the swollen joint count [SJC]). Numbered
arrows indicate plausible directions of the effect, based on observations of biologic phenomena and chronology. Genetic factors are present at
birth, before the appearance of anti–citrullinated protein antibodies (ACPAs), which precede disease onset and inflammation. B, Results from
the mediation analysis (see text). ACPAs and C-reactive protein (CRP) level are the main mediators of the effect of valine at position 11 on
SJC (systemic inflammatory pathway in red). However, part of the effect of valine at position 11 is mediated independently of CRP level (green
nonsystemic pathway).
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Using the same cohorts, we have recently shown
that HLA–DRB1 amino acid positions associated with RA
susceptibility are also associated with radiographic damage
as measured by the Larsen score (3). Since a certain level
of correlation is expected between radiographic and
nonradiographic measures of disease outcome, we first pro-
duced scatterplots of the Larsen score and nonradiographic
measures of outcome in the NOAR cohort (see Supple-
mentary Figure 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39780/abstract). The graphic pattern shows a poor correla-
tion, which was confirmed by a low Spearman’s rho (for
TJC with Larsen score, r5 0.06; for SJC with Larsen score,
r5 0.30; for HAQ score with Larsen score, r5 0.30; for
DAS28 with Larsen score, r5 0.29). Therefore, we con-
cluded that the Larsen score is not interchangeable with
nonradiographic measures of outcome; genetic factors
associated with the Larsen score will not automatically be
shared with nonradiographic measures.
We then tested the association of HLA–DRB1
amino acid positions conferring susceptibility with non-
radiographic measures of outcome in the NOAR cohort.
Results are presented for patients with inflammatory
polyarthritis in paragraphs and tables cited below. In uni-
variate analysis, effect sizes are compared to all other
amino acids at that position. In multivariate analysis, effect
sizes are compared to the reference group (haplotype
PAA).
CRP levels. Among all amino acids tested in uni-
variate analysis, valine at position 11 showed the strongest
association, with an increase of 16.27% in the CRP level per
copy (P5 2.21 3 1026) (Table 3). Amino acids at position
11 were all incorporated in the same multivariate model;
position 11 overall was associated with CRP level (P5 1.26
3 1026) (see Supplementary Table 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39780/abstract). Additionally, uni-
variate analysis showed that several amino acids at position
71 were significantly associated with CRP levels.
Univariate analysis showed that the valine-containing
haplotypes VKA and VRA were associated with
16.00% (P5 43 1024) and 15.30% (P5 0.008) increases,
respectively, in CRP level per copy (see Supplementary
Table 2, http://onlinelibrary.wiley.com/doi/10.1002/art.39780/
abstract). The serine-containing haplotype SEA was associ-
ated with a decrease of 17.81% (P5 0.001) in CRP levels.
Table 2. Characteristics of the patients in the NOAR and ERAS cohorts*
Characteristic
NOAR cohort
(n5 2,158)
ERAS cohort
(n5 329)
Recruitment years 1990–2008 1986–1999
Year of final follow-up 2011 2005
Satisfied ACR 1987 revised criteria for
RA during follow-up, no. (%)
1,951 (77) 316 (96)
Women, no. (%) 1,657 (65) 220 (67)
Age at symptom onset 55 (43–67) 54 (44–62)
Duration of symptoms at baseline, months 6 (3–12) 6 (3–11)
Duration of follow-up, years 3 (1–5) 7 (3–11)
Observations per patient
TJC and SJC 3 (1–5) 7 (3–11)
CRP 3 (1–5) –
ESR – 7 (3–11)
DAS28 3 (1–5) 7 (3–11)
HAQ 2 (1–4) 7 (3–11)
Ever seropositive for ACPAs (NOAR cohort)
or RF (ERAS cohort), no. (%)
713 (33) 297 (90)
Patients with at least 1 copy of SE, no. (%) 1,556 (62) 260 (79)
DAS28 at baseline 3.76 (2.79–4.78) 5.06 (4.19–5.84)
DAS28 at 5 years 2.71 (2.02–3.81) 4.21 (2.87–5.13)
CRP at baseline, mg/liter 8 (2–19.3) –
CRP at 5 years, mg/liter 6.3 (0–14.1) –
ESR at baseline, mm/hour – 36 (18–59)
ESR at 5 years, mm/hour – 22 (10–42)
HAQ score at baseline 0.875 (0.25–1.5) 1 (0.625–1.6875)
HAQ score at 5 years 0.875 (0.125–1.625) 1 (0.25–1.625)
* All were successfully genotyped patients for whom we had data on the Disease Activity Score in 28 joints
(DAS28) and the Health Assessment Questionnaire (HAQ) score. Except where indicated otherwise, values
are the median (interquartile range). NOAR5Norfolk Arthritis Register; ERAS5Early Rheumatoid
Arthritis Study; ACR5American College of Rheumatology; RA5 rheumatoid arthritis; TJC5 tender joint
count; SJC5 swollen joint count; CRP5C-reactive protein; ESR5 erythrocyte sedimentation rate;
ACPAs5 anti–citrullinated protein antibodies; RF5 rheumatoid factor; SE5 shared epitope.
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When all haplotypes were incorporated in a multivariate
model, VKA and VRA retained their associations. The 16-
haplotype model was significantly associated with CRP levels
(P5 2.23 1026) (Table 4). When effect sizes for association
with CRP level were plotted against effect sizes for susceptibil-
ity, a significant correlation was observed (r25 0.587,
P5 0.027) (Figure 1A), indicating that haplotypes that pre-
dict disease susceptibility also predict the level of systemic
inflammation.
SJC. Valine at position 11 was associated with
an increase of 0.30 swollen joints per copy (P5 7.51 3
1026) (Table 3). Position 11 was significantly associated
with the SJC (P5 0.002). The valine-containing haplotypes
VKA and VRA were associated with increases of 0.29
(P5 0.001) and 0.35 (P5 0.002) swollen joints per copy,
respectively (see Supplementary Table 2, http://onlinelibrary.
wiley.com/doi/10.1002/art.39780/abstract). The multivariate
model of all haplotypes was significantly associated with the
SJC (P5 0.0017), and the associations of VKA/VRA
retained significance (Table 4). Effect sizes in Results tables
are reported per copy of every allele, compared to a refer-
ence group. Effect sizes are larger if expressed for homozy-
gote carriers (e.g., the effect sizes for a VKA and VRA
homozygote compared to the reference PAA homozygote
are 0.68 and 0.80 joints, respectively). The 16-haplotype
model demonstrated significant correlation between suscep-
tibility and SJC (r25 0.589,P5 0.026) (Figure 1B).
TJC. There were no associations between indi-
vidual amino acids/haplotypes and the TJC.
DAS28. Valine at position 11 was associated with
an increase of 0.10 DAS28 units per copy (P5 0.002)
(Table 3). The multivariate model of 16 haplotypes was sig-
nificantly associated with the DAS28 (P5 0.0207), with the
valine-containing haplotype VRA being associated with an
increase of 0.20 DAS28 units per copy (P5 0.005) (Table
4). Effect sizes are larger if expressed for homozygote car-
riers and if the reference group is a homozygote protective
haplotype; the average difference in the DAS28 between a
VRA homozygote carrier and an SEA homozygote carrier
is 0.44 DAS28 units.
HAQ score. Multivariate analysis of all 16 hap-
lotypes showed increases of 0.07 and 0.08 HAQ score units
per copy in the haplotypes VKA and VRA, respectively,
with the model overall being associated with HAQ scores
(P5 0.0002) (Table 4).
Findings of subanalysis in RA patients and adjust-
ment for treatment. We conducted a subanalysis in patients
satisfying the ACR 1987 revised criteria for RA (13) (see
Supplementary Table 3, http://onlinelibrary.wiley.com/doi/10.
1002/art.39780/abstract). Results for CRP level were similar
in NOAR patients with RA (Supplementary Table 3). For
example, the VKA haplotype was associated with a 33.12%
increase in CRP level per copy (P5 2.443 1025) in multivar-
iate analysis. The associations reported above for the 16-
haplotype model in patients with inflammatory polyarthritis
remained significant after adjustment for treatment (data not
shown).
Validation with the ERAS cohort. Results for
SJC and the marker of inflammation used to calculate
the DAS28, in this case the ESR, were replicated within
the ERAS cohort (see Supplementary Table 4, http://
onlinelibrary.wiley.com/doi/10.1002/art.39780/abstract).
Valine at position 11 was significantly associated with an
increase of 0.82 swollen joints per copy (P5 4.553 1026),
and the haplotype VKA was significantly associated with a
10.94% increase in the ESR (P5 53 1025).
Findings of mediation analysis. Figure 2A shows
a directed acyclic graph summarizing plausible biologic paths
from genetic markers within HLA–DRB1 (valine at position
11 [Val11]) to disease activity/outcome (measured, for exam-
ple, by the SJC). First, we tested the association of Val11 and
CRP level with SJC in a bivariate analysis; this investigates
the effect of Val11 when not mediated through CRP level
(indicated by arrows 1–3 in Figure 2A) and the effect of other
factors (i.e., other genetic or environmental factors) that are
mediated by CRP level (indicated by arrow 6 in Figure 2A;
not including effects indicated by arrow 5). We found that
both Val11 (b coefficient of 0.39 [95% CI 0.19, 0.59], P5 1.6
3 1024) and CRP level (b coefficient of 0.03 [95% CI 0.02,
0.03], P5 2.8 3 10222) were independently associated with
SJC. Therefore, Val11 is also mediating its effect indepen-
dently of the CRP level through a nonsystemic pathway
(green pathway in Figure 2B).
In order to investigate whether the nonsystemic
effect of Val11 on SJC is direct (arrow 1 in Figure 2A) or
indirect through ACPA status (arrows 2 and 3 in Figure
2A), we added ACPA status into the model (trivariate analy-
sis, including Val11, CRP level, and ACPA status). We
obtained an association for Val11 with SJC that was almost
significant (b coefficient of 0.25 [95% CI 20.00, 0.50],
P5 0.051), but there was no significant association of ACPA
status with SJC (b coefficient of 0.22 [95% CI20.15, 0.59],
P5 0.24), indicating that it is not possible to determine
whether the nonsystemic effect of Val11 is direct or mediated
by ACPA status (green arrows in Figure 2B). However, in
view of the 95% CIs and P values reported herein, a direct
effect of Val11 on SJC is likely to explain the significant asso-
ciation of Val11 with SJC observed in the bivariate analysis.
Next, we investigated the association of Val11 with CRP level
using a bivariate analysis: 2 independent variables (ACPA
status and Val11) for 1 outcome variable (ln[CRP level1 1]).
This compares 2 pathways, indicated by arrow 5 versus
arrows 2 and 4 in Figure 2A. We did not detect any direct
effect of Val11 on CRP level (b coefficient of 0.04 [95% CI
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20.04, 0.11], P5 0.32), but there was a significant effect of
ACPA status on CRP level (b coefficient of 0.72 [95% CI
0.61, 0.82], P5 3.6 3 10238), indicating that most of the
effect of Val11 on CRP level is mediated by ACPA status
(systemic inflammatory pathway).
The effect of removing nonsignificant pathways from
Figure 2A is shown in Figure 2B. The effect of Val11 on dis-
ease activity/outcome is mainly mediated by ACPA status,
the effect of which is mainly mediated by systemic inflamma-
tion (pathway indicated by red arrows in Figure 2B), but the
effect of Val11 on disease activity/outcome is also mediated
through a nonsystemic pathway (green pathway in Figure
2B), most likely independently of ACPA status.
Finally, we decided to test whether the effect of
Val11 could be detected independently in ACPA-positive
patients and in ACPA-negative patients. This stratification
analysis is equivalent to an adjustment for ACPA status. As
we have shown above in the mediation analysis, ACPA sta-
tus is a path variable from Val11 to SJC. It is well known that
adjusting for a known path variable will remove the associa-
tion, unless Val11 also develops its effect on SJC indepen-
dently of ACPA status. As we have shown in the mediation
analysis, this is a plausible hypothesis, but our study lacked
sufficient power to provide a clear answer. The results of the
analysis after stratification by ACPA status are presented
in Supplementary Table 5 (http://onlinelibrary.wiley.com/
doi/10.1002/art.39780/abstract). Although the association of
genetic factors reached nominal significance in a few
instances (for the association of Val11 with SJC in ACPA-
negative patients, b coefficient of 0.18 [95% CI 0.01, 0.35],
P5 0.038), most associations did not remain significant
after stratification by ACPA status. This pattern of associa-
tion (highly significant P value before stratification, lack of
significance after stratification) confirms that ACPA status
is an important path variable in the etiology of clinical
inflammation, but this analysis is inconclusive with regard to
a minor independent effect of genetic factors on SJC (due
to an underpowered study design).
DISCUSSION
In this study, we performed a detailed examination
of associations of HLA–DRB1 positions 11/13, 71, and 74
with inflammatory polyarthritis and RA disease activity
and outcome measures (HAQ score and DAS28 and its
subcomponents). We demonstrate that amino acids at
position 11/13, outside of the classical SE, show the stron-
gest association with clinical and laboratory measures of
inflammation. Valine at position 11 shows the greatest
effect, while serine at the same position is protective;
amino acids at position 71 also contribute. Indeed, analysis
showed that haplotypes predicting disease susceptibility
also predict levels of systemic inflammation and clinical
inflammation (Figures 1A and B), and the same risk hier-
archy of effect sizes is observed for susceptibility and for
measures of inflammation.
The effect of valine at position 11 on SJC (clinical
inflammation) is mainly mediated by ACPA status and
systemic (or laboratory-determined) inflammation (CRP
level). However, we could also show that this association is
independent of CRP level; this is an important finding,
since several studies have now shown that RA can be
active with no elevation of CRP level and can progress in
the absence of detectable systemic inflammation (7,8). In
the absence of clinical signs of inflammation (no swollen
joints), radiographic progression was shown to be similar
between patients with normal CRP levels and those with
CRP levels indicating active disease; however, in the absence
of laboratory-determined active inflammation (CRP level
,1 mg/dl), SJC determined radiographic progression (8).
Therefore, it seems that clinical inflammation rather than
laboratory-determined inflammation is associated with
radiographic progression and mortality (8).
We have shown in a previous study (3) that RA
genetic susceptibility markers within HLA–DRB1 predict
radiographic damage in RA. In the present study, we tested
hypotheses regarding the mechanisms of action of genetic
variations and showed that the same genetic markers within
HLA–DRB1 have an effect on clinical inflammation (SJC)
and laboratory-determined or systemic inflammation (CRP
level) independently of each other. Therefore, amino acid
positions 11/13, 71, and 74 within HLA–DRB1 are likely
to mediate their effect on radiographic outcome through
at least 2 distinct inflammatory pathways. Drawing the
directed acyclic graph differently by substituting SJC for
CRP level, assuming that clinical inflammation (SJC)
causes laboratory-determined inflammation (CRP level),
did not affect our conclusion (data not shown).
Only 33% of patients are positive for ACPAs in
the NOAR cohort, while the proportion is higher in the
ERAS cohort (90%). This is mainly because NOAR is a
primary care inception cohort recruiting all patients who
have had$2 swollen joints for.4 weeks within a defined
geographic area. It is worth noting that the level of recruit-
ment is very high. Consequently, inflammatory polyarthritis
and RA patients with very low disease severity (and more
likely to be ACPA negative) are also included in the
NOAR cohort. Subsequently, 32% of inflammatory polyar-
thritis patients have been found to have drug-free remission
of their disease by the 3-year follow-up visit (19), which
indicates a high proportion of patients with disease of low
severity. The tertiary care ERAS cohort preferentially
recruits patients with higher disease severity; the DAS28,
CRP level, and HAQ score are higher in the ERAS cohort
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than in the NOAR cohort (Table 2). It is also noteworthy
that the French Etude et Suivi des Polyarthrites
Indifferenciees Recentes (ESPOIR) cohort, an inception
cohort similar to the NOAR cohort but consisting of RA
patients recruited from tertiary care, has a similar propor-
tion of ACPA-positive patients (38.7%) (21). Having a
large proportion of ACPA-negative patients in the NOAR
cohort represents a strength of our study, as it provides suf-
ficient power to determine the role of ACPAs in the path to
clinical and laboratory-determined inflammation.
It is remarkable that CRP levels are controlled by
RA susceptibility loci within the HLA region in active dis-
ease. CRP levels are known to be partially genetically deter-
mined (but not by HLA genes) (22,23), and haplotypes of
common single-nucleotide polymorphisms (SNPs) within
the CRP locus have been reported in some (24), but not all,
studies to correlate with CRP levels in RA patients. For
example, we were unable to replicate the correlation of
CRP haplotypes with CRP levels in a cohort of RA patients
with high disease activity (the Biologics in Rheumatoid
Arthritis Genetics and Genomics Study Syndicate cohort)
(25), possibly because the study was underpowered (fewer
than 600 patients). The use of CRP levels to guide treat-
ment decisions has been questioned (24), since carriers of
low CRP–associated genetic variants could still have active
disease and show disease progression in the absence of
laboratory-determined inflammation (7,8). As a possible
genetic explanation of this observation, we show in the pre-
sent study that RA susceptibility loci within the HLA region
are correlated with the SJC (clinical inflammation) inde-
pendently of the CRP level (laboratory-determined inflam-
mation). A limitation of the current study is that haplotypes
of common SNPs within the CRP locus were not available
in samples from the NOAR and ERAS cohorts, so we
could not undertake a formal comparison of the effect sizes
of CRP haplotypes and HLA haplotypes on CRP levels
within the same cohort.
The findings of the current study support and build
on previous findings that HLA–DRB1 susceptibility risk
haplotypes encompassing the same 3 positions also corre-
late with radiographic and mortality data (3). Neither
markers of inflammation nor the DAS28 and its compo-
nents were analyzed in that study. The current findings may
suggest a mechanistic explanation, because we have shown
that CRP levels are particularly influenced by the 16-
haplotype model. There is a well-established relationship
between time-integrated CRP levels and radiographic pro-
gression in RA patients (6); our model suggests that the
effect of genetic determinants of radiographic damage is
mediated by inflammation. The association between the 16-
haplotype model and the SJC likely confirms the SJC as a
surrogate indicator of active synovitis/inflammation.
Stronger associations were found between the 16-
haplotype model and objective variables studied, such as
CRP levels and SJC. The results with the TJC (a more sub-
jective variable) and with the DAS28 (a composite variable)
reflect that the inclusion of subjective variables such as TJC
diminishes the association between the DAS28 and disease
severity; this finding is corroborated by an independent
study (5). In the future, TJC may even be removed alto-
gether from outcome calculations, as it may not be a sensi-
tive enough indicator of joint damage or disease activity.
A greater understanding of genetic susceptibility to
RA and its adverse disease outcomes may lead to a strati-
fied medicine approach (26) with 16 risk categories, as
patients with increased susceptibility to developing RA are
also more likely to have a worse disease course, requiring
earlier and more aggressive intervention. The current study
shows that genetic changes influence levels of inflammation,
which in turn lead to joint damage. The “treat-to-target”
strategies (27) have shown that control of disease activity, as
measured by composite scoring methods, has resulted in
improving outcomes, but the current study suggests that con-
trolling objective measures of inflammation (CRP levels and
SJC) may be the key factor.
In conclusion, our findings demonstrate an associa-
tion of amino acids at position 11/13 within the HLA–DRB1
gene (but outside the SE), and also of haplotypes involving
amino acid positions 11/13, 71, and 74, with objective disease
outcome measures. In addition, our findings describe a
genetic basis for the increased inflammatory response that is
known to lead to radiographic progression in patients with
inflammatory polyarthritis or RA.
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